Cell Therapy: cGMP Facilities and Manufacturing

Advanced therapies constitute one of the most complex, organizational, and regulatory areas currently approached by clinical researchers in order to explore new therapeutic applications. Basic scientists and clinicians trying to implement cell therapies into clinical practice, may feel overwhelmed by the apparently endless regulatory requirements that apply. However, regulatory agencies have primary responsibility on patient safety and law enforcement are, and should be, their main considerations. Cell- and tissue-based therapies have the potential to treat many conditions, where present conventional treatments are inadequate. The current approach to cell- and tissue-based therapy development requires using good manufacturing production facilities through master and working cell banks. Facilities need to be purpose-designed and accredited by their national medicinal regulatory body and production scientists need to work in close tandem with quality assurances and ethics committees to absolutely ensure the safety of this cellular products.

[1]  李幼升,et al.  Ph , 1989 .

[2]  Michael G Fehlings,et al.  Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. , 2008, Neurosurgical focus.

[3]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[4]  Donald W. Fink FDA Regulation of Stem Cell–Based Products , 2009, Science.

[5]  S. Cole,et al.  Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .

[6]  Insoo Hyun,et al.  The bioethics of stem cell research and therapy. , 2010, The Journal of clinical investigation.

[7]  Sheila MacNeil,et al.  Progress and opportunities for tissue-engineered skin , 2007, Nature.

[8]  Patrick L. Taylor,et al.  iPS Cells: Mapping the Policy Issues , 2009, Cell.

[9]  Michele De Luca,et al.  Isolation and production of cells suitable for human therapy: challenges ahead. , 2009, Cell stem cell.

[10]  M. Rao,et al.  Musings on genome medicine: is there hope for ethical and safe stem cell therapeutics? , 2009, Genome Medicine.

[11]  Karl-Heinz Krause,et al.  Phenazopyridine induces and synchronizes neuronal differentiation of embryonic stem cells , 2009, Journal of cellular and molecular medicine.

[12]  Giulio Cossu,et al.  New ISSCR guidelines underscore major principles for responsible translational stem cell research. , 2008, Cell stem cell.

[13]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[14]  D. G. Halme,et al.  FDA regulation of stem-cell-based therapies. , 2006, The New England journal of medicine.

[15]  R. Brooks,et al.  Articular cartilage tissue engineering: today's research, tomorrow's practice? , 2009, The Journal of bone and joint surgery. British volume.

[16]  F. Gage,et al.  Setting Standards for Human Embryonic Stem Cells , 2003, Science.

[17]  Gu Weijun,et al.  Strategies and new developments in the generation of pluripotent stem cells. , 2009 .

[18]  D. Gastineau,et al.  Infrastructure Development for Human Cell Therapy Translation , 2007, Clinical pharmacology and therapeutics.

[19]  M. Rao,et al.  Alternative sources of pluripotent stem cells: scientific solutions to an ethical dilemma. , 2008, Stem cells and development.

[20]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[21]  K. Plath,et al.  Generation of human induced pluripotent stem cells from dermal fibroblasts , 2008, Proceedings of the National Academy of Sciences.

[22]  J. Cigudosa,et al.  Spontaneous human adult stem cell transformation. , 2005, Cancer research.